.png){kind=icon}
.png){kind=icon}
Return
Descemet Stripping Only in Fuchs Endothelial Corneal Dystrophy: Results of a Randomized Clinical Trial of Topical Ripasudil and Directions for Future Innovation
.png){kind=icon}
OA
AI
K
F
S
DOI：10.1016/j.ajo.2026.06.014.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To review history of Descemet Stripping Only (DSO) in Fuchs Endothelial Corneal Dystrophy (FECD), describe the results of a clinical trial of topical ripasudil after DSO (K-321-201 study), and discuss future directions.
Keywords:
Fuchs dystrophy
corneal endothelium
descemet stripping only
Ripasudil
Rhoassociated kinase inhibitor
Corneal Surgery
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.2
Papers:
3.0W
Citations:
2.8W
Organization
Cited Papers